Skip to content

Study · Animal study (in vivo) · mouse · 2008

3 results

Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency.

Xue S, Wasserfall CH, Parker M, Brusko TM, McGrail S, McGrail K, Moore M, Campbell-Thompson M, Schatz DA, Atkinson MA, Haller MJ

Annals of the New York Academy of Sciences1 Dec 2008Cited by 46 (Europe PMC)

PMID19120286 (opens in a new tab)DOI10.1196/annals.1447.049 (opens in a new tab)PepBankPUB-19120286
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In NOD mice with new-onset diabetes, exendin‑4 increased regulatory T-cell frequency versus saline.

    In plain wordsIn mice with new diabetes, exendin‑4 increased regulatory immune cell frequency compared with saline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseRegulatory T-cell frequency
    Study

    mousen: not reported in source

    NOD mice with recently diagnosed type 1 diabetes
    Comparator
    Saline-treated NOD mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.2 microg/mouse/day · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    In comparison to that of saline-treated control NOD mice, the frequency of Tregs was increased in Ex-4-treated mice.
    1 context sentence
    Summary · context
    We evaluated the effect of Ex-4 (Byetta; 0.2 microg/mouse/day for 30 days) treatment on the frequency and function of Tregs and changes in the cytokine profile of NOD mice with recently diagnosed T1D.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In NOD mice, exendin‑4 showed a trend toward increased regulatory T-cell suppression, limited by small sample size.

    In plain wordsIn mice, exendin‑4 showed a trend toward stronger immune cell suppression, but the sample was small.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseRegulatory T-cell suppression
    Study

    mousen: not reported in source

    NOD mice with recently diagnosed type 1 diabetes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.2 microg/mouse/day · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Suppression assays demonstrated a trend towards increased Treg suppression after administration of Ex-4, but were limited by small sample size.
    1 context sentence
    Summary · context
    We evaluated the effect of Ex-4 (Byetta; 0.2 microg/mouse/day for 30 days) treatment on the frequency and function of Tregs and changes in the cytokine profile of NOD mice with recently diagnosed T1D.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In NOD mice with new-onset diabetes, exendin‑4 induced IL-10 production.

    In plain wordsIn mice with new diabetes, exendin‑4 induced IL-10 production.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseIL-10 production
    Study

    mousen: not reported in source

    NOD mice with recently diagnosed type 1 diabetes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.2 microg/mouse/day · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Lastly, Ex-4 treatment induced production of IL-10, indicating a possible shift towards a more Th2-like phenotype.
    1 context sentence
    Summary · context
    We evaluated the effect of Ex-4 (Byetta; 0.2 microg/mouse/day for 30 days) treatment on the frequency and function of Tregs and changes in the cytokine profile of NOD mice with recently diagnosed T1D.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.